ENTRY       D12368                      Drug
NAME        Epcoritamab (USAN/INN);
            Epcoritamab (genetical recombination) (JAN);
            Epcoritamab-bysp;
            Epkinly (TN);
            Tepkinly (TN)
PRODUCT     EPKINLY (Genmab US)
FORMULA     C6471H9999N1735O2007S44
EXACT_MASS  145533.1407
MOL_WEIGHT  145622.9121
SEQUENCE    (A chain)
            EVKLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR IRSKYNNYAT
            YYADSVKDRF TISRDDSKSS LYLQMNNLKT EDTAMYYCVR HGNFGNSYVS WFAYWGQGTL
            VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP
            EFEGGPSVFL FPPKPKDTLM ISRTPEVTCV VVAVSHEDPE VKFNWYVDGV EVHNAKTKPR
            EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
            PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFLLYSKLTV
            DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPG
            (B chain)
            EVQLVESGGG LVQPDRSLRL SCAASGFTFH DYAMHWVRQA PGKGLEWVST ISWNSGTIGY
            ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCAKDI QYGNYYYGMD VWGQGTTVTV
            SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPEFE
            GGPSVFLFPP KPKDTLMISR TPEVTCVVVA VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
            YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
            EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSRLTVDKS
            RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G
            (C chain)
            QAVVTQEPSF SVSPGGTVTL TCRSSTGAVT TSNYANWVQQ TPGQAFRGLI GGTNKRAPGV
            PARFSGSLIG DKAALTITGA QADDESIYFC ALWYSNLWVF GGGTKLTVLG QPKAAPSVTL
            FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
            LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
            (D chain)
            EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
            RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPITFGQ GTRLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: A22-A98, A152-A208, A228-C214, A234-B231, A237-B234, A269-A329, A375-A433, B22-B96, B149-B205, B225-D214, B266-B326, B372-B430, C22-C90, C137-C196, D23-D88, D134-D194)
  TYPE      Peptide
REMARK      Therapeutic category: 4291
            Product: D12368<JP/US>
EFFICACY    Antineoplastic
  DISEASE   Diffuse large B-cell lymphoma, not otherwise specified [DS:H02434]
            High-grade B-cell lymphoma [DS:H00008]
  TYPE      Monoclonal antibody, bispecific antibody
TARGET      CD3E [HSA:916] [KO:K06451]
            CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(916+931)  Hematopoietic cell lineage
            hsa04658(916)  Th1 and Th2 cell differentiation
            hsa04659(916)  Th17 cell differentiation
            hsa04660(916)  T cell receptor signaling pathway
BRITE       USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Epcoritamab
                D12368  Epcoritamab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D12368  Epcoritamab (USAN/INN); Epcoritamab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3E
                 D12368  Epcoritamab (USAN/INN) &lt;JP/US&gt;
                CD20
                 D12368  Epcoritamab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12368
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12368
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12368
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12368
DBLINKS     CAS: 2134641-34-0
///
